Patients Prevention for a healthier, more productive society During Anthropy 2025: Rebooting Britain, web editor Nicole Raleigh spoke with David Gillen, chief medical officer at Norgine.
Patients How pharma is tackling new direct-to-patient programmes At Reuters Pharma USA, executives from AstraZeneca, Gilead, Kyowa Kirin, and EVERSANA discussed the what, why, and how of direct-to-patient models.
Patients Direct-to-patient is more than just telehealth – with EVERSA... Hear from EVERSANA's Faruk Abdullah in this video interview as he explains why direct-to-patient strategies go beyond telehealth.
Patients Unifying observational research with a next-generation virtu... Observational research is core to drug development, helping researchers understand the natural history of diseases and the real-world impact of treatments on patients.
Patients New Boehringer US Head Brian Hilberdink talks GLP-1s, DTx an... At Reuters Pharma USA, editor-in-chief Jonah Comstock caught up with Brian Hilberdink, the new head of US human pharma at Boehringer Ingelheim.
Patients For the continuum of mental health we need a whole system, h... If we don’t address the mental health of young people, that mental health challenge will advance into the adult population of tomorrow.
News Lilly bags FDA okay for Wegovy pill rival orforglipron Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk's first-to-market Wegovy pill.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.